Search results
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Genetic counsellors are specially trained healthcare professionals with extensive scientific knowledge who spend time talking to families living with inherited conditions.
The following questions are often asked by people contacting Retina UK.
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
The BBC covered a story on Monday 24 May about optogenetics partially restoring the sight of a man living with retinitis pigmentosa in France.
Mark your special day, whilst fundraising for people with inherited sight loss.
Our community support us in many different ways, from completing surveys, volunteering, raising awareness and fundraising.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
